Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.43 |
| ▸ | DRD3 | P35462 | 13/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | DRD4 | P21917 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7648782 | 0.99 | DRD2 (0.42) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL7535062 | 0.97 | DRD2 (0.41) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL7476712 | 0.95 | DRD2 (0.40) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL7481005 | 0.94 | DRD2 (0.39) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL7539113 | 0.92 | DRD3 (0.39) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL7475220 | 0.92 | HTR2A (0.39) | DRD2DRD3HTR2ADRD4HTR2C | |
| SCHEMBL7422472 | 0.89 | DRD2 (0.43) | DRD2DRD3HTR2AHTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL7477971 | 0.88 | DRD2 (0.42) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL7475928 | 0.88 | MAPT (0.39) | DRD2DRD3ADRA1A | |
| SCHEMBL7988073 | 0.87 | TP53 (0.43) | DRD2DRD3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888332-B1 | N-Azacycloalkyl Alkyl Dibenzothiophene Carboxamides: Dopamine Receptor Subtype Specific Ligands | NEUROGEN CORP (US) | 2001-05-30 | — | — | EP | claimed |
| US-6221869-B1 | N-aminoalkyldibenzothiophenecarboxamides new dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | claimed |
| US-6429312-B2 | SELECTIVE DOPAMINE D3 ANTAGONISTS FREE FROM NEUROLOGICAL SIDE EFFECTS OF CONVENTIONAL NEUROLEPTICS | NEUROGEN CORPORATION | 2002-08-06 | — | — | US | disclosed |
| US-20010044461-A1 | Novel N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands | YUAN JUN (US) | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044461-A1 | Novel N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands | CNR1, GLRA1, SIGMAR1 | DRD2 51/4885DRD3 96/4885HTR2A 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.